These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 21220060

  • 1. Targeting remission by 8 weeks: when should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor?
    Cooper-Kazaz R, Rigbi A, Lerer B.
    Compr Psychiatry; 2011; 52(1):9-16. PubMed ID: 21220060
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
    Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B.
    Arch Gen Psychiatry; 2007 Jun; 64(6):679-88. PubMed ID: 17548749
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team.
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.
    Bitran S, Farabaugh AH, Ameral VE, LaRocca RA, Clain AJ, Fava M, Mischoulon D.
    Int Clin Psychopharmacol; 2011 Jul; 26(4):206-12. PubMed ID: 21278577
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L.
    J Affect Disord; 2016 May 15; 196():225-33. PubMed ID: 26938965
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM, Llorca PM, Despiegel N, Verpillat P.
    Encephale; 2004 May 15; 30(2):158-66. PubMed ID: 15107719
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Early symptom change prediction of remission in depression treatment.
    Katz MM, Meyers AL, Prakash A, Gaynor PJ, Houston JP.
    Psychopharmacol Bull; 2009 May 15; 42(1):94-107. PubMed ID: 19204654
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association analysis of SIGMAR1 with major depressive disorder and SSRI response.
    Kishi T, Yoshimura R, Okochi T, Fukuo Y, Kitajima T, Okumura T, Tsunoka T, Kawashima K, Yamanouchi Y, Kinoshita Y, Umene-Nakano W, Naitoh H, Nakamura J, Ozaki N, Iwata N.
    Neuropharmacology; 2010 Jun 15; 58(7):1168-73. PubMed ID: 20178807
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.